Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia

16Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) represent a rare and heterogenous tumor entity. Importantly, the highly proliferative subgroup of neuroendocrine carcinoma (GEP-NEC) is characterized by high resistance to conventional chemotherapy. Consequently, there is an urgent need to identify novel therapeutic targets, especially for GEP-NEC. Thus, we focused on Inhibitor of apoptosis protein (IAP) family members survivin and XIAP that orchestrate inhibition of apoptosis, induce resistance against chemotherapeutics and facilitate tumor metastasis. Copy number gains (CNGs) could be detected by microarray comparative genomic hybridization for survivin and XIAP in 60 % and 26.7 % of all GEP-NENs, respectively. Immunohistochemical staining of tissue specimens from 77 consecutive patients with GEP-NEN demonstrated increased survivin protein expression levels in tissue specimens of highly proliferative GEP-NEC or GEP-NEN located in the stomach and colon. In contrast, XIAP overexpression was associated with advanced tumor stages. Knockdown of survivin and XIAP markedly reduced cell proliferation and tumor growth. In vitro, YM155 induced apoptotic cell death accompanied by a reduction in cell proliferation and inhibited GEP-NEC xenograft growth. Taken together, our data provide evidence for a biological relevance of these IAPs in GEP-NEN and support a potential role of survivin as therapeutic target especially in the subgroup of aggressive GEP-NEC.

References Powered by Scopus

The hallmarks of cancer

24266Citations
N/AReaders
Get full text

Reporting recommendations for tumor marker prognostic studies (REMARK)

1221Citations
N/AReaders
Get full text

IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis

1091Citations
N/AReaders
Get full text

Cited by Powered by Scopus

BRAF <sup>V600E</sup> mutation: A promising target in colorectal neuroendocrine carcinoma

41Citations
N/AReaders
Get full text

Multifaceted mechanisms of cisplatin resistance in long-term treated urothelial carcinoma cell lines

32Citations
N/AReaders
Get full text

Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer

25Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Dizdar, L., Oesterwind, K. A., Riemer, J. C., Werner, T. A., Mersch, S., Möhlendick, B., … Krieg, A. (2017). Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia. Oncotarget, 8(5), 8369–8382. https://doi.org/10.18632/oncotarget.14207

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

53%

Researcher 5

29%

Professor / Associate Prof. 3

18%

Readers' Discipline

Tooltip

Medicine and Dentistry 11

69%

Agricultural and Biological Sciences 2

13%

Biochemistry, Genetics and Molecular Bi... 2

13%

Pharmacology, Toxicology and Pharmaceut... 1

6%

Save time finding and organizing research with Mendeley

Sign up for free